{"entity":{"id":"paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024","kind":"paper","name":"GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma","aka":[],"tldr":"A new regimen built around brentuximab vedotin cured more patients with advanced Hodgkin lymphoma than the intensive BEACOPP standard, and did so with less toxicity, including less damage to fertility.","summary":"International randomised phase 3 trial of 1,500 patients with newly diagnosed advanced-stage classical Hodgkin lymphoma comparing PET-guided BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone) with PET-guided escalated BEACOPP, four or six cycles depending on interim PET.\n\nFour-year progression-free survival was 94.3 percent with BrECADD against 90.9 percent with escalated BEACOPP, and treatment-related morbidity was lower (about 42 versus 59 percent), with faster recovery of gonadal function. BrECADD is now the GHSG standard for advanced disease.","asOf":"2026-09-18","links":[{"label":"Lancet 2024","url":"https://doi.org/10.1016/S0140-6736(24)01315-1"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/38971175/"}],"tags":[],"related":[],"cancers":["advanced-stage-classical-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["brentuximab-vedotin","doxorubicin","dacarbazine","etoposide","cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["hd21"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet"],"dependsOn":[],"notes":[],"journal":"The Lancet","year":2024,"doi":"10.1016/S0140-6736(24)01315-1","pmid":"38971175","authors":"Borchmann P, Ferdinandus J, Schneider G, et al.","paperType":"rct","findings":["Four-year progression-free survival 94.3 percent with BrECADD versus 90.9 percent with escalated BEACOPP.","Treatment-related morbidity about 42 versus 59 percent, with better recovery of gonadal function."],"whatItMeans":"For fit younger patients treated in the intensive German tradition, BrECADD replaces escalated BEACOPP; how it compares with nivolumab-AVD from S1826 is the open question.","caveats":["Patients were mostly under 60 and fit enough for intensive therapy.","Follow-up for late effects such as second cancers is still short."],"changedPractice":true,"participants":1500},"route":"/key-papers/paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024/","neighbours":{"cancer":[{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/"}],"drug":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"}],"trial":[{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/"}],"journal":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/"}]}}